Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Objectives Coronavirus disease 2019 (COVID-19) -associated pulmonary aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The objectives of this multinational study were to determine the prevalence of CAPA in patients with COVID-19 in intensive care units (ICU) and to investigate risk factors for CAPA as well as outcome. Methods The European Confederation of Medical Mycology (ECMM) conducted a multinational study including 20 centres from nine countries to assess epidemiology, risk factors and outcome of CAPA. CAPA was defined according to the 2020 ECMM/ISHAM consensus definitions. Results A total of 592 patients were included in this study, including 11 (1.9%) patients with histologically proven CAPA, 80 (13.5%) with probable CAPA, 18 (3%) with possible CAPA and 483 (81.6%) without CAPA. CAPA was diagnosed a median of 8 days (range 0–31 days) after ICU admission predominantly in older patients (adjusted hazard ratio (aHR) 1.04 per year; 95% CI 1.02–1.06) with any form of invasive respiratory support (HR 3.4; 95% CI 1.84–6.25) and receiving tocilizumab (HR 2.45; 95% CI 1.41–4.25). Median prevalence of CAPA per centre was 10.7% (range 1.7%–26.8%). CAPA was associated with significantly lower 90-day ICU survival rate (29% in patients with CAPA versus 57% in patients without CAPA; Mantel–Byar p < 0.001) and remained an independent negative prognostic variable after adjusting for other predictors of survival (HR 2.14; 95% CI 1.59–2.87, p ≤ 0.001). Conclusion Prevalence of CAPA varied between centres. CAPA was significantly more prevalent among older patients, patients receiving invasive ventilation and patients receiving tocilizumab, and was an independent strong predictor of ICU mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Koehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951 · cited 3×
“In this study, we have classified all patients according to the recently published standardized ECMM/ISHAM consensus definitions for CAPA [19], and found a median CAPA prevalence among the participating centres of 10.”
InfluentialSelf-citationCOVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547
Self-citationBartoletti, M., Pascale, R., Cricca, M., Rinaldi, M., Maccaro, A., Bussini, L., Fornaro, G., Tonetti, T., Pizzilli, G., Francalanci, E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1065 · Cited by 473 · cited 5×
“Some previous, single-centre studies, have indicated that CAPA may prolong stay in hospital and invasiveness of ventilation [29], and may also be associated with higher mortality compared with non-CAPA patients [6,7], whereas others did not show any impact onmortality [12].”
InfluentialVerweij, P. E., Rijnders, B. J. A., Brüggemann, R. J. M., Azoulay, E., Bassetti, M., Blot, S., Calandra, T., Clancy, C. J., Cornely, O. A., Chiller, T., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06091-6 · Cited by 459 · cited 1×
“bronchoscopies not done [17]), as well as various different criteria applied for definition of aspergillosis in COVID-19 patients [16,18].”
Self-citationPrevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19
Alanio, A., Dellière, S., Fodil, S., Bretagne, S., & Mégarbane, B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30237-x · Cited by 457 · cited 1×
“Some previous, single-centre studies, have indicated that CAPA may prolong stay in hospital and invasiveness of ventilation [29], and may also be associated with higher mortality compared with non-CAPA patients [6,7], whereas others did not show any impact onmortality [12].”
White, P. L., Dhillon, R., Cordey, A., Hughes, H., Faggian, F., Soni, S., Pandey, M., Whitaker, H., May, A., Morgan, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1298 · Cited by 445 · cited 5×
“However, other factors described before as being associated with CAPA development, like the use of systemic corticosteroids [7] or azithromycin [21], were not significantly associated with CAPA in our study.”
InfluentialSelf-citationCOVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Arastehfar, A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P., Krause, R., Cornely, O. A., S. Perlin, D., Lass-Flörl, C., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6020091 · Cited by 421
Self-citationCOVID-19–associated Pulmonary Aspergillosis
van Arkel, A. L. E., Rijpstra, T. A., Belderbos, H. N. A., van Wijngaarden, P., Verweij, P. E., & Bentvelsen, R. G. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1038le · Cited by 370
COVID-19–Associated Pulmonary Aspergillosis, March–August 2020
Salmanton-García, J., Sprute, R., Stemler, J., Bartoletti, M., Dupont, D., Valerio, M., Garcia-Vidal, C., Falces-Romero, I., Machado, M., de la Villa, S., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2704.204895 · Cited by 269
Self-citation
Cited by
COVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Self-citationThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Self-citationThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
Hoenigl, M., Egger, M., Price, J., Krause, R., Prattes, J., & White, P. L. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01859-22 · Cited by 51
Self-citation
Metadata
- Authors
- Prattes, J., Wauters, J., Giacobbe, D. R., Salmanton-García, J., Maertens, J., Bourgeois, M., Reynders, M., Rutsaert, L., Van Regenmortel, N., Lormans, P., Feys, S., Reisinger, A. C., Cornely, O. A., Lahmer, T., Valerio, M., Delhaes, L., Jabeen, K., Steinmann, J., Chamula, M., Bassetti, M., Hatzl, S., Rautemaa-Richardson, R., Koehler, P., Lagrou, K., Hoenigl, M., Debaveye, Y., Miceli, M. H., Tudesq, J.-J., Paul, G., Krause, R., Linhofer, M., Frost, J., Zechner, P., Kochanek, M., Eller, P., Jenks, J. D., Volpi, S., Bellanger, A.-P., White, P. L., Goldman, G. H., Bowyer, P., Rokas, A., Gago, S., Pelosi, P., Robba, C., Gangneux, J.-P., Lass-Floerl, C., Machado, M., & Muñoz, P.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 28
- Issue
- 4
- Pages
- 580-587
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W3193623972
- Cited by
- 233
- References
- 32
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.